Literature DB >> 28157424

A Rho-Associated Kinase Inhibitor Protects Permeability in a Cell Culture Model of Ocular Disease, and Reduces Aqueous Flare in Anterior Uveitis.

Hiroshi Yamada1, Masahiko Yoneda2, Shingo Inaguma3, Masahiko Gosho4, Yusuke Murasawa5, Zenzo Isogai5, Masahiro Zako1,6.   

Abstract

PURPOSE: Recent clinical and experimental studies have reported favorable results when using Rho-associated kinase (ROCK) inhibitors for ocular disease, and in cell culture. Disruption of the human, nonpigmented ciliary epithelial cells (HNPCECs) that comprise the blood-aqueous barrier (BAB) induces anterior uveitis; these cells therefore provide a useful cell model of ocular disease. In this study, we examined the effects of ROCK inhibitors in anterior uveitis and in HNPCECs.
METHODS: Aqueous flare values and intraocular pressures (IOPs) were determined in patients with anterior uveitis, 2 weeks after administration of ripasudil hydrochloride hydrate, a commercial ROCK inhibitor used to treat glaucoma or ocular hypertension. We also investigated the effects of Y-27632, a second ROCK inhibitor, in HNPCECs following exposure to matrix metalloproteinases (MMPs) and human tumor necrosis factor-alpha (TNF-α).
RESULTS: Patients with anterior uveitis, glaucoma, or ocular hypertension, referred to the Aichi Medical University from February to July 2015, were enrolled. Thirty eyes from 25 outpatients were studied. Aqueous flare values and IOPs were significantly decreased 2 weeks after ripasudil hydrochloride hydrate treatment, with no adverse events. In a cultured HNPCEC monolayer, permeability was markedly increased following exposure to MMPs-1, 3, 9, and TNF-α, with these effects attenuated by exposure to Y-27632. In cultured HNPCECs, Y-27632 provoked a marked alteration in cytoskeletal morphology without a significant change in expression levels of claudin-1 and occludin.
CONCLUSION: ROCK inhibitors may confer favorable effects in anterior uveitis, possibly due to a reorganized BAB, although the relevant mechanisms remain unclear.

Entities:  

Keywords:  anterior uveitis; aqueous flare; inhibitor of Rho-associated kinase; intraocular pressure; nonpigmented ciliary epithelium

Mesh:

Substances:

Year:  2017        PMID: 28157424     DOI: 10.1089/jop.2016.0085

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  5 in total

Review 1.  Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.

Authors:  Nuno Moura-Coelho; Joana Tavares Ferreira; Carolina Pereira Bruxelas; Marco Dutra-Medeiros; João Paulo Cunha; Rita Pinto Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-07       Impact factor: 3.117

Review 2.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

Review 3.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

Review 4.  [Rho kinase inhibitors as new local therapy option in primary open angle glaucoma].

Authors:  C Erb; K Konieczka
Journal:  Ophthalmologe       Date:  2021-01-05       Impact factor: 1.059

5.  Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension.

Authors:  Mami Yasuda; Kei Takayama; Takayuki Kanda; Manzo Taguchi; Hideaki Someya; Masaru Takeuchi
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.